Cover Image

Ceftazidime/Tobramycin Co-Loaded Chitosan-Coated Zein Nanoparticles against Antibiotic-Resistant and Biofilm-Producing <i>Pseudomonas aeruginosa</i> and <i>Klebsiella pneumoniae</i>

This study aimed to co-encapsulate ceftazidime and tobramycin in zein nanoparticles coated with chitosan and to characterize and evaluate the antibacterial and antibiofilm activity against antibiotic-resistant <i>Pseudomonas aeruginosa</i> and <i>Klebsiella pneumoniae</i>. Ze...

Full description

Saved in:

Bibliographic Details
Main Authors:	Luís André de Almeida Campos (Author), Azael Francisco Silva Neto (Author), Alexsandra Maria Lima Scavuzzi (Author), Ana Catarina De Souza Lopes (Author), Nereide Stela Santos-Magalhães (Author), Isabella Macário Ferro Cavalcanti (Author)
Format:	Book
Published:	MDPI AG, 2024-02-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Exploring Antibiotic-Potentiating Effects of Tobramycin-Deferiprone Conjugates in <i>Pseudomonas aeruginosa</i>
by: Karan Gandhi, et al.
Published: (2023)

Itaconic Acid Increases the Efficacy of Tobramycin against <i>Pseudomonas aeruginosa</i> Biofilms
by: Duy-Khiet Ho, et al.
Published: (2020)

Review of Ceftazidime-Avibactam for the Treatment of Infections Caused by <i>Pseudomonas aeruginosa</i>
by: George L. Daikos, et al.
Published: (2021)

Antimicrobial Synergy Testing: Comparing the Tobramycin and Ceftazidime Gradient Diffusion Methodology Used in Assessing Synergy in Cystic Fibrosis-Derived Multidrug-Resistant <i>Pseudomonas aeruginosa</i>
by: Ijeoma N. Okoliegbe, et al.
Published: (2021)

Role of Tobramycin in the Induction and Maintenance of Viable but Non-Culturable <i>Pseudomonas aeruginosa</i> in an In Vitro Biofilm Model
by: Gianmarco Mangiaterra, et al.
Published: (2020)

Comparative In Vitro Activity of Ceftazidime-Avibactam, Imipenem-Relebactam, and Meropenem-Vaborbactam against Carbapenem-Resistant Clinical Isolates of <i>Klebsiella pneumoniae</i> and <i>Pseudomonas aeruginosa</i>
by: Anthony Sophonsri, et al.
Published: (2024)

Antibacterial Efficacy of Liposomal Formulations Containing Tobramycin and <i>N</i>-Acetylcysteine against Tobramycin-Resistant <i>Escherichia coli</i>, <i>Klebsiella pneumoniae</i>, and <i>Acinetobacter baumannii</i>
by: Reem E. Alarfaj, et al.
Published: (2022)

Comparative Efficacy of Continuous Ceftazidime Infusion vs. Intermittent Bolus against In Vitro Ceftazidime-Susceptible and -Resistant <i>Pseudomonas aeruginosa</i> Biofilm
by: Cristina El Haj, et al.
Published: (2024)

Ceftazidime and Usnic Acid Encapsulated in Chitosan-Coated Liposomes for Oral Administration against Colorectal Cancer-Inducing <i>Escherichia coli</i>
by: Jaqueline Barbosa de Souza, et al.
Published: (2024)

Evaluation of Tobramycin and Ciprofloxacin as a Synergistic Combination Against Hypermutable <i>Pseudomonas Aeruginosa</i> Strains via Mechanism-Based Modelling
by: Vanessa E. Rees, et al.
Published: (2019)

Liposome-Encapsulated Tobramycin and IDR-1018 Peptide Mediated Biofilm Disruption and Enhanced Antimicrobial Activity against <i>Pseudomonas aeruginosa</i>
by: Nouf M. Alzahrani, et al.
Published: (2022)

Genomic Analysis of Ceftazidime/Avibactam-Resistant GES-Producing Sequence Type 235 <i>Pseudomonas aeruginosa</i> Isolates
by: Raúl Recio, et al.
Published: (2022)

Probability of Target Attainment of Tobramycin Treatment in Acute and Chronic <i>Pseudomonas aeruginosa</i> Lung Infection Based on Preclinical Population Pharmacokinetic Modeling
by: Bruna Bernar Dias, et al.
Published: (2022)

Bloodstream Infections Due to Wild-Type <i>Pseudomonas aeruginosa</i>: Carbapenems and Ceftazidime/Avibactam Prescription Rate and Impact on Outcomes
by: Carlo Pallotto, et al.
Published: (2024)

A Cationic Porphyrin, ZnPor, Disassembles <i>Pseudomonas aeruginosa</i> Biofilm Matrix, Kills Cells Directly, and Enhances Antibiotic Activity of Tobramycin
by: Neha Patel, et al.
Published: (2020)

<i>Pseudomonas aeruginosa</i> Biofilm Formation, Infections and Treatments
Published: (2021)

Comparative Evaluation of Vitek 2 and Etest versus Broth Microdilution for Ceftazidime/Avibactam and Ceftolozane/Tazobactam Susceptibility Testing of <i>Enterobacterales</i> and <i>Pseudomonas aeruginosa</i>
by: Arhodoula Papadomanolaki, et al.
Published: (2022)

Susceptibility of Meropenem-Resistant and/or Carbapenemase-Producing Clinical Isolates of <i>Enterobacterales</i> (<i>Enterobacteriaceae</i>) and <i>Pseudomonas aeruginosa</i> to Ceftazidime-Avibactam and Ceftolozane-Tazobactam as Assessed by In Vitro Testing Methods
by: Venere Cortazzo, et al.
Published: (2022)

Treatment Heterogeneity in <i>Pseudomonas aeruginosa</i> Pneumonia
by: Aisling R. Caffrey, et al.
Published: (2022)

Effect of Different Piperacillin-Tazobactam Dosage Regimens on Synergy of the Combination with Tobramycin against <i>Pseudomonas aeruginosa</i> for the Pharmacokinetics of Critically Ill Patients in a Dynamic Infection Model
by: Jessica R. Tait, et al.
Published: (2022)

Clinical and Economic Burden of Carbapenem-Resistant Infection or Colonization Caused by <i>Klebsiella pneumoniae</i>, <i>Pseudomonas aeruginosa</i>, <i>Acinetobacter baumannii</i>: A Multicenter Study in China
by: Xuemei Zhen, et al.
Published: (2020)

Antimicrobial Treatment of <i>Pseudomonas aeruginosa</i> Severe Sepsis
by: Johnny Zakhour, et al.
Published: (2022)

The Basis for Natural Multiresistance to Phage in <i>Pseudomonas aeruginosa</i>
by: Christine Pourcel, et al.
Published: (2020)

Population Pharmacokinetics and Probability of Target Attainment of Different Dosing Regimens of Ceftazidime in Critically Ill Patients with a Proven or Suspected <i>Pseudomonas aeruginosa</i> Infection
by: Annabel Werumeus Buning, et al.
Published: (2021)

Evaluation of Aztreonam and Ceftazidime/Avibactam Synergism against <i>Klebsiella pneumoniae</i> by MALDI-TOF MS
by: Camila Mörschbächer Wilhelm, et al.
Published: (2023)

The <i>Klebsiella pneumoniae</i> carbapenemase (KPC) β-Lactamase Has Evolved in Response to Ceftazidime Avibactam
by: Sona Garsevanyan, et al.
Published: (2023)

Spiramycin Disarms <i>Pseudomonas aeruginosa</i> without Inhibiting Growth
by: Matteo Calcagnile, et al.
Published: (2023)

Bacteriophage-Antibiotic Combination Therapy against <i>Pseudomonas aeruginosa</i>
by: Guillermo Santamaría-Corral, et al.
Published: (2023)

Sub-Inhibitory Antibiotic Exposure and Virulence in <i>Pseudomonas aeruginosa</i>
by: Charlotte Nolan, et al.
Published: (2021)

Detection of extended-spectrum β-lactamase in <i>Pseudomonas aeruginosa</i>
by: Aggarwal Ritu, et al.
Published: (2008)

Trends in <i>Pseudomonas aeruginosa</i> (<i>P. aeruginosa</i>) Bacteremia during the COVID-19 Pandemic: A Systematic Review
by: Qin Xiang Ng, et al.
Published: (2023)

Suboptimal Concentrations of Ceftazidime/Avibactam (CAZ-AVI) May Select for CAZ-AVI Resistance in Extensively Drug-Resistant <i>Pseudomonas aeruginosa</i>: In Vivo and In Vitro Evidence
by: Inmaculada Lopez-Montesinos, et al.
Published: (2022)

Comparative Analysis of Complicated Urinary Tract Infections Caused by Extensively Drug-Resistant <i>Pseudomonas aeruginosa</i> and Extended-Spectrum β-Lactamase-Producing <i>Klebsiella pneumoniae</i>
by: Elena Sendra, et al.
Published: (2022)

Formulation and characterization of tobramycin-chitosan nanoparticles coated with zinc oxide nanoparticles
by: Nusaiba.K. Al-nemrawi, et al.
Published: (2022)

Recent Advance in Small Molecules Targeting RhlR of <i>Pseudomonas</i> <i>aeruginosa</i>
by: Taehyeong Lim, et al.
Published: (2022)

Ceftazidime-Avibactam Treatment for <i>Klebsiella pneumoniae</i> Bacteremia in Preterm Infants in NICU: A Clinical Experience
by: Andrea Marino, et al.
Published: (2023)

In Vitro Activity of Ceftolozane-Tazobactam against <i>Escherichia coli</i>, <i>Klebsiella pneumoniae</i> and <i>Pseudomonas aeruginosa</i> Obtained from Blood Cultures from Sentinel Public Hospitals in South Africa
by: Olga Perovic, et al.
Published: (2023)

Antimicrobial Contribution of Chitosan Surface-Modified Nanoliposomes Combined with Colistin against Sensitive and Colistin-Resistant Clinical <i>Pseudomonas aeruginosa</i>
by: Valentina Laverde-Rojas, et al.
Published: (2020)

In Vitro Evaluation of Increasing Avibactam Concentrations on Ceftazidime Activity against Ceftazidime/Avibactam-Susceptible and Resistant KPC-Producing <i>Klebsiella pneumoniae</i> Clinical Isolates
by: Marta Palombo, et al.
Published: (2023)

<i>N</i>-Alkane Assimilation by <i>Pseudomonas aeruginosa</i> and Its Interactions with Virulence and Antibiotic Resistance
by: Balázs Libisch
Published: (2024)